What Egetis Therapeutics does

Egetis Therapeutics AB (publ) is a Swedish public pharmaceutical company headquartered in Stockholm, founded in 2006 (originally as PledPharma AB) and listed on Nasdaq Stockholm under ticker EGTX. The company focuses on late-stage development and commercialization of treatments for serious rare diseases with significant unmet medical needs in the orphan drug segment, operating through a wholly owned subsidiary, Rare Thyroid Therapeutics International AB, acquired in November 2020. It commercializes via a focused in-house organization in Europe and North America, with strategic partnerships in the Rest of World.

The company has two lead assets: Emcitate (tiratricol), a triiodothyronine (T3) analogue approved by the European Commission in February 2025 as the first and only treatment for MCT8 deficiency (Allan-Herndon-Dudley syndrome), under FDA Priority Review with a PDUFA date of September 28, 2026, and commercially launched in Germany in May 2025; and Aladote (calmangafodipir), a first-in-class drug candidate in pivotal Phase IIb/III development for paracetamol/acetaminophen overdose, effective beyond the 8-hour NAC window. Both assets hold Orphan Drug Designation in the US and EU, and Emcitate additionally holds Rare Pediatric Disease Designation and Breakthrough Therapy Designation, with composition-of-matter patent protection anticipated to extend to 2045.

Egetis generates revenue through product sales (Emcitate post-EU approval and Named Patient Programs in 25+ countries), licensing fees, and royalties from strategic partners. Pricing is not publicly disclosed, but the revenue model targets ultra-rare disease patient populations via Managed Access Programs and a US Expanded Access Program. Headcount is reported at 11-50, the shareholder base is led by Frazier Life Sciences (16.65%) and other healthcare-specialist investors, and the company raised SEK 350 million (~USD 38 million) in April 2026 to fund US commercialization and potential indication expansion.

Name

Egetis Therapeutics

Legal name

Egetis Therapeutics AB (publ)

Website

https://egetis.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Egetis Therapeutics is a Swedish public pharmaceutical company (Nasdaq Stockholm: EGTX) developing and commercializing late-stage orphan drugs for serious rare diseases, with lead product Emcitate (tiratricol) approved in the EU and under FDA review for MCT8 deficiency, and Aladote (calmangafodipir) in late-stage development for paracetamol overdose.

Ownership category

akta.pro rank

Product category

Orphan Drug Specialty Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)

akta.pro secondary industries

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Rare Endocrine & Growth Disorder Therapies (HLAIAIAJ)

Keywords

• Orphan drug development
• Rare disease therapeutics
• Thyroid hormone analogues
• MCT8 deficiency treatment
• Paracetamol overdose antidote

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Product sales: Revenue generated primarily through sales of own products after gaining market approval. Emcitate is approved in the EU (February 2025) and launched in Germany in May 2025. Named Patient sales are already occurring.
2. Licensing fees and royalties: Named Patient sales from Emcitate as well as license fees and royalties through strategic partnerships are the main sources of revenue. License fees are received when initiating partnerships or at defined milestones (non-recurring). Royalties are recurring revenue received when a drug is sold in the market.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Egetis Therapeutics develops and commercializes proprietary orphan drug therapies for serious rare diseases. Its lead product Emcitate (tiratricol) is a T3 analogue approved in the EU for MCT8 deficiency (Allan-Herndon-Dudley syndrome) and under FDA Priority Review, and Aladote (calmangafodipir) is a first-in-class candidate to reduce acute liver injury from paracetamol overdose. Both target life-threatening conditions with no adequate existing treatments.

Product overview

Egetis Therapeutics is an innovative pharmaceutical company focused on late-stage development and commercialization of treatments for serious rare diseases with significant unmet medical needs in the orphan drug segment. The company has two lead products: Emcitate (tiratricol), approved in the EU for MCT8 deficiency and under FDA review for US approval, and Aladote (calmangafodipir), a first-in-class candidate for paracetamol overdose, currently in clinical development. Both products target rare diseases with no adequate treatments available.

Differentiator

Problem solved

Functional benefit

Brands

• Emcitate: Lead investigational therapy for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome (AHDS). Approved in EU in February 2025.
• Aladote

Products and services

• Emcitate (tiratricol) Emcitate is a triiodothyronine (T3) analogue developed for the treatment of MCT8 deficiency (Allan-Herndon-Dudley syndrome), a rare X-linked genetic disorder. It restores thyroid hormone signaling in cells with defective MCT8 transporter and significantly reduces serum T3 levels. Approved in the EU (February 2025) and under FDA Priority Review with PDUFA target action date of September 28, 2026.
• Aladote (calmangafodipir) Aladote is a first-in-class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. Its mechanism is effective even in the time window beyond 8 hours post-ingestion when standard N-acetylcysteine (NAC) treatment is no longer effective. Granted Orphan Drug Designation in the U.S. and EU.

Quantifiable outcome

• Statistically and clinically significant reduction in serum T3 levels demonstrated in Triac Trial I (multinational Phase 2b study) and long-term real-life study of 67 patients over up to 6 years.
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Erasmus University Medical CentercoreStrategic or Co-development PartnerLed the multinational Phase 2b Triac Trial I and investigator-initiated long-term real-life study evaluating Emcitate in 67 patients over up to 6 years across 33 centers. Key academic collaborator providing clinical trial expertise.
• MCT8-AHDS FoundationcoreStrategic or Co-development PartnerPatient advocacy foundation working to improve quality of life for MCT8-AHDS patients, support families, raise awareness, and advance research. Collaborates with Egetis on awareness initiatives including the Behind the Mystery TV episode.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Alnylam Pharmaceuticals: Commercial-stage biopharmaceutical company developing RNA interference therapeutics for rare genetic diseases. Comparable in addressing serious rare genetic conditions with novel mechanisms of action and global orphan drug commercialization strategies.
• Ultragenyx Pharmaceutical: Late-stage rare disease biopharmaceutical company developing and commercializing treatments for serious rare and ultra-rare genetic diseases. Closely comparable business model with focus on first-in-class orphan therapies, regulatory exclusivity, and targeted specialty commercialization.
• Mirum Pharmaceuticals: Commercial-stage rare disease company focused on serious liver and neurological diseases (Livmarli, Cholbam). Comparable in scale, late-stage orphan focus, and similar commercial strategy targeting ultra-rare patient populations. Egetis's newly appointed CMO previously led clinical development at Mirum.
• Calliditas Therapeutics: Swedish specialty pharmaceutical company focused on rare diseases, headquartered in Stockholm. Comparable in domicile, size, and orphan drug focus (Tarpeyo for IgA nephropathy). Egetis's VP Technical Operations previously served as VP Operations at Calliditas.
• Sarepta Therapeutics: Commercial-stage biopharmaceutical company developing precision genetic medicines for rare diseases. Comparable in addressing rare genetic disorders with high unmet need, premium orphan pricing, and focused commercial organization. Egetis's President of North America previously held a VP role at Sarepta.

Broad incumbents

• BioMarin Pharmaceutical: Established global rare disease biopharmaceutical company with a broad portfolio across multiple rare disease franchises. Comparable orphan drug business model and patient access strategies, though significantly larger and more diversified than Egetis.
• Swedish Orphan Biovitrum (Sobi): Swedish-based international rare disease biopharmaceutical company focused on rare diseases and specialty care. Comparable in domicile, regulatory pathway expertise, and European rare disease commercialization infrastructure, though Sobi operates at substantially larger scale.
• Ipsen: Global specialty biopharmaceutical group with a strong rare disease franchise (including rare endocrine and metabolic disorders). Comparable in addressing rare endocrine conditions with limited patient populations and leveraging orphan drug regulatory pathways.
• Recordati Rare Diseases: Specialty pharmaceutical division of Recordati focused on treatments for rare diseases. Comparable in commercial focus on orphan drug distribution, patient access programs, and partnership-based entry into ultra-rare disease markets globally.

Emerging players

• Intercept Pharmaceuticals: Biopharmaceutical company focused on liver diseases with therapies addressing serious non-viral liver conditions. Comparable in liver-focused therapeutic development relevant to Egetis's Aladote program for paracetamol-induced acute liver injury.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/egetis-therapeutics-ab

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Egetis Therapeutics